FDA Clearance Tracker · P100010-S098
Arctic Front Advance, Arctic Front Advance Pro and Freezor MAX Cardiac Cryoablation Catheters
Last checked: Nov 20, 2026Latest source record: Jun 23, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Jun 23, 2020
Approved
Time to decision
242 days
Received Oct 25, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P100010-S098
- Device name
- Arctic Front Advance, Arctic Front Advance Pro and Freezor MAX Cardiac Cryoablation Catheters
- Applicant
- Medtronic Cryocath, LP
- Applicant location
- Mounds View, MN
- Received
- Oct 25, 2019
- Decided
- Jun 23, 2020
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P100010
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the Arctic Front Advance and Arctic Front Advance Pro Cardiac Cryoablation Catheter is indicated for the treatment of drug refractory recurrent symptomatic paroxysmal and persistent atrial fibrillation (episode duration less than 6 months). The Freezor MAX Cardiac Cryoablation Catheter is used as an adjunctive device in the endocardial treatment of paroxysmal and persistent atrial fibrillation (episode duration less than 6 months) in conjunction with the Arctic Front Cryocatheter for the following uses:1) Gap cryoablation to complete electrical isolation of the pulmonary veins;2 Cryoablation of focal trigger sites; and3) Creation of ablation line between the inferior vena cava and the tricuspid valve.
Source documents
Other decisions for Medtronic Cryocath, LP
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P100010-S110 · Decided Jun 18, 2021 · 231 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
K202620 · Decided Nov 13, 2020 · 64 days after receipt
Device type: Catheter, Steerable (DRA) · Cardiology
K183174 · Decided Nov 26, 2018 · 10 days after receipt
Device type: Catheter, Steerable (DRA) · Cardiology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.